이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Arctic Bioscience 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Christer Valderhaug

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	0.2%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

We're Hopeful That Arctic Bioscience (OB:ABS) Will Use Its Cash Wisely

Jul 08

Here's Why We're Not Too Worried About Arctic Bioscience's (OB:ABS) Cash Burn Situation

Apr 09

CEO

Christer Valderhaug (52 yo)

no data

테뉴어

Mr. Christer L. Valderhaug serves as Chief Executive Officer at Arctic Bioscience AS. He serves as Senior Advisor at Converto Holding As (formerly known as Converto AS) since November 2016. He came from th...

리더십 팀

이름	위치	테뉴어	보상	소유권
Harald Nordal	Co-Founder & Chairman	8.8yrs	데이터 없음	데이터 없음
Christer Valderhaug	Chief Executive Officer	no data	데이터 없음	0.19% NOK 485.8k
Hogne Hallaraker	Founder & Chief Scientific Officer	6.3yrs	데이터 없음	1.77% NOK 4.6m
Jone Slinning	Chief Financial Officer	2.3yrs	데이터 없음	0.052% NOK 134.6k
Per Sæbo	Chief Operating Officer	12yrs	데이터 없음	0.090% NOK 234.0k
Daniele Mancinelli	Chief Technical Officer	12yrs	데이터 없음	0.027% NOK 69.8k
Steffen Eidal	Senior Vice President of Sales & Marketing	2.3yrs	데이터 없음	데이터 없음
Yuming Feng	Executive Vice President of Global Business Development	5.8yrs	데이터 없음	데이터 없음
Runhild Gammelsæter	Global Medical Director	4.9yrs	데이터 없음	0.098% NOK 252.7k

5.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ABS 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Harald Nordal	Co-Founder & Chairman	8.8yrs	데이터 없음	데이터 없음
Jostein Dalland	Independent Board Member	4.3yrs	데이터 없음	데이터 없음
Asbjorn Solevagseide	Board Member	5.3yrs	데이터 없음	데이터 없음
Jan Vartdal	Board Member	8.8yrs	데이터 없음	4.1% NOK 10.6m
Per Eggesbo	Board Member	8.5yrs	데이터 없음	데이터 없음
Hu Cao	Board Member	3.4yrs	데이터 없음	데이터 없음
Tore Andreas Tonseth	Board Member	3.5yrs	데이터 없음	데이터 없음
Marita Holstad	Director	3.5yrs	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: ABS 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.

Arctic Bioscience 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Global Medical Director recently bought kr160k worth of stock

Chief Executive Officer recently bought kr299k worth of stock

Less than half of directors are independent

Global Medical Director recently bought kr101k worth of stock

Less than half of directors are independent

Board Member recently bought kr220k worth of stock

Recent updates

Arctic Bioscience Announces New Positive Data Showing Anti-Inflammatory Effects of Phospholipid Esters from Herring Roe in Immune Cells

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings released

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

Arctic Bioscience AS to Report Q4, 2023 Results on Mar 01, 2024

New major risk - Revenue and earnings growth

New major risk - Share price stability

Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS to Report Fiscal Year 2023 Results on Apr 09, 2024

Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial

Arctic Bioscience AS Provides Revenue Guidance for the Year 2023

New minor risk - Financial data availability

Arctic Bioscience AS Provides Earnings Guidance for the Year 2023

Consensus EPS estimates upgraded to kr1.74 loss, revenue downgraded

Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing

Full year 2022 earnings: Revenues miss analyst expectations

Global Medical Director recently bought kr160k worth of stock

Chief Executive Officer recently bought kr299k worth of stock

Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.

Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK

Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK

Arctic Bioscience AS to Report Fiscal Year 2022 Results on Mar 29, 2023

Price target decreased to kr15.00

Less than half of directors are independent

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb

Arctic Bioscience AS Announces Update on Clinical Trial Application for HRO350 Phase IIb

Consensus forecasts updated

Arctic Bioscience as Provides Revenue Guidance for the Year 2022

We're Hopeful That Arctic Bioscience (OB:ABS) Will Use Its Cash Wisely

Global Medical Director recently bought kr101k worth of stock

Less than half of directors are independent

Board Member recently bought kr220k worth of stock

Here's Why We're Not Too Worried About Arctic Bioscience's (OB:ABS) Cash Burn Situation

Full year 2021 earnings: Revenues miss analyst expectations

Arctic Bioscience Provides Earnings Guidance for the Fiscal Year 2022

Arctic Bioscience Announces Termination Danielle Glenn as CFO

Arctic Bioscience AS Provides Earnings Guidance for the Year 2021

Arctic Bioscience Receives Grant from the Research Council of Norway for Its Pharmaceutical Development

Arctic Bioscience Provides Financial Guidance for the Fiscal Year 2021

Arctic Bioscience Signs 3-Year Agreement Worth 75 Million NOK with Smerud Medical Research International to Conduct Clinical Study on Psoriasis

Board Member recently bought kr498k worth of stock

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령